Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

This trial tests a medication called gabapentin enacarbil (GEn) to treat nighttime agitation and restless legs syndrome (an uncontrollable urge to move the legs at rest) in people living with Alzheimer's disease, since these nighttime symptoms can severely disrupt sleep and caregiver wellbeing. **You may be eligible if...** - You are 55 or older with a doctor's diagnosis of Alzheimer's-type dementia - You have nighttime agitation (significant restlessness and disruptive behavior at night) - You have been assessed and found to have restless legs syndrome by the study team - You are medically stable and your medications have not changed in the past 14 days - You are able to swallow medications and walk (with or without assistance) - You live with a caregiver (family member or hired help) who lives with you full-time **You may NOT be eligible if...** - You are already being treated for restless legs syndrome with gabapentin or the study drug - You have Parkinson's disease or another disorder causing tremor - You consume alcohol regularly (as it can increase sedation with this medication) - You have severe kidney impairment or are on dialysis - You are taking high-dose opioid pain medications - You have severe psychosis - You live independently in the community without a live-in caregiver Talk to your doctor to see if this trial is right for you.